Volunteers in the United Kingdom have received doses of an experimental vaccine designed to protect against H5N1, a bird flu strain that has infected bird populations globally and some mammal species. The UK Health Security Agency characterizes the current threat to humans as low, with documented human infections predominantly occurring through direct contact with infected animals.
The trial aims to enroll 4,000 participants, with three-quarters of recruitment taking place at 26 sites across England and Scotland, and the remainder in the United States. The study targets two priority groups: individuals employed in the poultry industry and adults over age 65. The vaccine relies on messenger RNA technology, the same platform used in current coronavirus vaccines, which researchers say enables rapid production and scaling in pandemic scenarios. Dr. Rebecca Clark, the trial’s national coordinating investigator, emphasized that although human-to-human transmission has not yet occurred readily, such transmission must be considered a plausible future risk warranting preventive measures.
Since 2024, there have been 116 confirmed human cases of H5N1 infection worldwide, nearly all connected to animal contact. The trial will evaluate vaccine safety and its capacity to generate adequate immune protection, with potential licensing for emergency use if circumstances warrant. Should deployment become necessary, production would occur at Moderna’s facility in Harwell, Oxfordshire, which currently manufactures coronavirus vaccines for the UK. The facility has baseline capacity of 100 million annual doses, expandable to 250 million doses during a pandemic response.
MRNA technology offers advantages over traditional egg-based flu vaccine production methods, particularly when viral strains prove lethal to the eggs required in conventional manufacturing. The Coalition for Epidemic Preparedness Innovations has allocated £40 million in funding for the trial, with Moderna committing to providing rapid and affordable vaccine supplies to low and middle-income countries in any future pandemic, aiming to prevent the disparities in vaccine access observed during the coronavirus pandemic.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI